CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20(+) NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xinyuan, Zhao, Juanjuan, Guo, Xiangqian, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401875/
https://www.ncbi.nlm.nih.gov/pubmed/37537626
http://dx.doi.org/10.1186/s13045-023-01488-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401875/
https://www.ncbi.nlm.nih.gov/pubmed/37537626
http://dx.doi.org/10.1186/s13045-023-01488-4

Ejemplares similares